Machine signal
Active cluster buy — 4 distinct insiders, $369.9K, window ends Sep 30, 2026.
Figures computed from official regulatory filings — .
Analysttarget 9.75 USD (+231%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 5.62% · institutions 13.83% · short 3.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Anixa Biosciences Inc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
343 buys43 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Catelani Michaeltrack record | Buy | $15.6K | conv 64 |
| SEC |
| Baskies Arnold Mtrack record | Buy | $13.8K | conv 45Cluster | SEC |
| KUMAR AMITtrack record | Buy | $19.5K | conv 49Cluster | SEC |
| Titterton Lewis H jrtrack record | Buy | $131.9K | conv 32 | SEC |
| Titterton Lewis H jrtrack record | Buy | $27.3K | conv 30 | SEC |
| KUMAR AMITtrack record | Buy | $8.3K | conv 29 | SEC |
| KUMAR AMITtrack record | Buy | $13.8K | conv 29 | SEC |
| KUMAR AMITtrack record | Buy | $17.4K | conv 28 | SEC |
| Baskies Arnold Mtrack record | Exercise | $18.8K | SEC |
| Baskies Arnold Mtrack record | Other | $18.8K | SEC |
| Baskies Arnold Mtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KUMAR AMITtrack record | Buy | $17.2K | conv 28 | SEC |
| KUMAR AMITtrack record | Buy | $10.7K | conv 28 | SEC |
| KUMAR AMITtrack record | Buy | $11.2K | conv 28 | SEC |
| KUMAR AMITtrack record | Buy | $17.3K | conv 28 | SEC |
| Titterton Lewis H jrtrack record | Buy | $41.6K | conv 28 | SEC |
| Titterton Lewis H jrtrack record | Buy | $9.2K | conv 29 | SEC |
| KUMAR AMITtrack record | Buy | $15.2K | conv 29 | SEC |
| Titterton Lewis H jrtrack record | Buy | $7.5K | conv 44 | SEC |
| KUMAR AMITtrack record | Buy | $52.5K | conv 49 | SEC |
| Baskies Arnold Mtrack record | Buy | $30.4K | conv 34 | SEC |
| Baskies Arnold Mtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Titterton Lewis H jrtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gottschalk Emily | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Catelani Michaeltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |